Flex Pharma,Inc. (NASDAQ:FLKS) Files An 8-K Other Events

Flex Pharma,Inc. (NASDAQ:FLKS) Files An 8-K Other Events
Item 8.01 Other Events.

Story continues below

On March 26, 2018, Flex Pharma, Inc. ("the Company") issued a press release announcing the topline data from its exploratory Phase 2 clinical trial of FLX-787 in Multiple Sclerosis patients with frequent muscle cramps/spasms and spasticity. The Company will host a conference call and live webcast with a slide presentation on Monday, March 26, at 8:45 a.m. EDT. A copy of this press release and slide presentation are filed herewith as Exhibits 99.1 and 99.2, respectively, and the information contained therein is incorporated by reference into this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits


Flex Pharma, Inc. Exhibit
EX-99.1 2 pressrelease991.htm EXHIBIT 99.1 Exhibit Flex Pharma Reports Positive Topline Data from Exploratory Phase 2 Trial of FLX-787 in Multiple Sclerosis •FLX-787 reduced cramp/spasm frequency (p=0.0017) and increased cramp-free days (p=0.0457) in MS patients in a pre-specified analysis of the parallel treatment phase•Treating physicians reported improvement in spasticity in patients receiving FLX-787 as measured by the Clinical Global Impression of Change (CGI-C) in pre-specified analyses (p=0.01 parallel period,…
To view the full exhibit click here

About Flex Pharma,Inc. (NASDAQ:FLKS)

Flex Pharma, Inc. is a biotechnology company. The Company develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps (EAMCs). The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. The Company operates through developing and commercializing products for nocturnal leg cramps, muscle cramps, spasms and spasticity associated with severe neuromuscular conditions, and exercise-associated muscle cramps segment. The Company’s lead drug product candidate is FLX-787, which is in the Phase II clinical trial stage. It is developing a consumer brand and products specifically formulated to treat athletes suffering from EAMCs.

An ad to help with our costs